This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): TGN 255
Description: Flovagatran is an intravenous small-molecule direct thrombin inhibitor. Flovagatran is a synthetic molecule, intended to overcome many of the issues associated with heparin use. It is thought that with flovagatran, anti-coagulation can be rapidly established and stably maintained without dose adjustment. On cessation of therapy flovagatran is rapidly and predictably cleared. Furthermore, the product is approximately 85% non-renally excreted, suggesting that standard doses may be used in renally compromised patients.
Deal Structure: In April 2008, PAION announced that it acquired the world-wide rights to flovagatran from Trigen for an upfront payment of approximately EUR 0.3 million. PAION will be required to make a milestone payment in the event flovagatran receives regulatory approval or is licensed or sold in a major market but will not be required to pay ongoing royalties.
Additional information available to subscribers only: